Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation
NCT06717958 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76
Last updated 2025-07-02
Summary
maintenance of AML or MDS patients with known IDH1 mutation after allogeneic stem cell transplantation within past 100 days
Conditions
Interventions
- DRUG
-
Ivosidenib 250 MG (milligram)
oral
Sponsors & Collaborators
-
Technische Universität Dresden
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-06-17
- Primary Completion
- 2029-10-01
- Completion
- 2030-02-01
Countries
- Germany
Study Locations
More Related Trials
-
Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia
NCT06643195 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients
NCT01929408 ·Status: COMPLETED
-
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
NCT04493164 ·Status: RECRUITING ·Phase: PHASE2
-
a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia
NCT07007949 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase II Study on Allogeneic Stem Cell Transplantation in Patients With Active Acute Leukemia
NCT01814488 ·Status: COMPLETED ·Phase: PHASE2
-
Panobinostat Maintenance After HSCT fo High-risk AML and MDS
NCT04326764 ·Status: TERMINATED ·Phase: PHASE3
-
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
NCT03839771 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
NCT04044209 ·Status: WITHDRAWN ·Phase: PHASE2
-
Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide
NCT04361058 ·Status: WITHDRAWN ·Phase: PHASE1
-
Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia
NCT04250051 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML
NCT02461537 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).
NCT01835587 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse
NCT01995578 ·Status: COMPLETED ·Phase: PHASE2
-
Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML
NCT01277484 ·Status: UNKNOWN ·Phase: PHASE1
-
A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia
NCT02826642 ·Status: WITHDRAWN ·Phase: PHASE1
-
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia
NCT00002549 ·Status: UNKNOWN ·Phase: PHASE3
-
Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
NCT06543381 ·Status: RECRUITING ·Phase: PHASE1
-
Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102)
NCT02016781 ·Status: COMPLETED ·Phase: PHASE2
-
Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome
NCT00043134 ·Status: UNKNOWN ·Phase: PHASE3
-
Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders
NCT04761770 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant
NCT00986804 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia
NCT06427330 ·Status: RECRUITING ·Phase: PHASE2
-
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
NCT01801046 ·Status: TERMINATED ·Phase: PHASE1
-
HDM201 Added to CT in R/R or Newly Diagnosed AML
NCT03760445 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study
NCT07108530 ·Status: RECRUITING ·Phase: PHASE2